Answers are grounded in this paper and cite their sources.
Progress on dengue vaccines shows promise, yet immune challenges complicate broad use in populations.
Development of vaccines against dengue has been designated a priority for over 75 years. The completion of Phase III trials and licensing of multiple dengue vaccines have been significant accomplishments of the last 15 years. Despite that progress, a vaccine suitable for broad use has not yet been identified. The scientific challenges of multiple dengue viral serotypes, immune imprinting from previous infections, and immune enhancement of infection and disease remain formidable obstacles to this goal. Further investments in clinical research of natural dengue virus infections and participants in dengue vaccine trials will be needed to enable the development and testing of the next generation of dengue vaccines.
No takes yet. Share an insight, caveat, or question.
Rothman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: